

FOR IMMEDIATE RELEASE

For more information, contact
Jill Shoemaker
Executive VP of Investor Relations
(970) 282.0156 x16
jshoemaker@st-renatus.com

ST. RENATUS' TECHNOLOGY PRESENTED OVER SEAS **The world's first needle-free anesthetic turns heads at IADR event in Spain**

Fort Collins, Colo. – September 2, 2010 – St. Renatus, the Fort Collins-based company dedicated to commercializing the world's first needle-free dental anesthetic, was featured at the 88th annual International Association for Dental Research (IADR) General Session Exhibition July 14-17, 2010 in Barcelona, Spain.

The event took place at the Centre Convencions Internacional Barcelona (CCIB) and brought together members of the IADR's European Region, British, Continental European, Irish, Israeli and Scandinavian Divisions.

St. Renatus is currently undergoing U.S. Food and Drug Administration (FDA) clinical testing for its nasal mist anesthetic, which is administered through the nasal cavity and suitable for use in procedures involving most of the upper teeth.

This new drug product was presented within a poster titled "Nasal Spray for Anesthesia of Maxillary Teeth" by Dr. Fadi Ayoub, a proponent of the technology and full-time Assistant Professor in the restorative department at the University at Buffalo School of Dental Medicine in New York. Dr. Ayoub and his staff administered Phase 1 and 2 clinical trials at their university.

Dr. Ayoub said the nasal mist grabbed the attention of many members at the event, including the Scandinavian dentists and researchers, who believed the product would benefit children the most, because in their countries the government provides dental care for all school children from preschool through high school.

"I believe it will change how people think of dentistry world-wide. It was evident when the nasal mist grabbed the attention of many members at the event," said Dr. Ayoub.

St. Renatus' CEO, Steve Merrick said it is beneficial to present at these types of meetings because it includes a third party review and discussion of new technology, which in return helps everyone understand the science being conducted.

"These meetings allow top dental researchers to review many different clinical and laboratory studies and provide feedback on the scientific methods used and the findings. Dental anesthesia is a niche field and this type of professional review might lead to better

ideas related to the technology. It is a positive step to have independent scientists review and share their comments with you,” said Mr. Merrick.

St. Renatus anticipates completion of FDA Phase 3 clinical trials in the first quarter of 2011. Upon completion of the trials, the company will then submit the New Drug Application (NDA).

- ### -

About St. Renatus

St. Renatus, LLC was founded to commercialize the world’s first needle-free dental anesthetic suitable for use in procedures involving most of the upper teeth. By bringing this product to market, St. Renatus aims to create a better experience for dentists and qualifying patients by using an accurate and sophisticated method to anesthetize the upper teeth without the risk and pain of a needle. For more information on St. Renatus, visit www.st-renatus.com or call 970.282.0156.



Steve Merrick, St. Renatus' CEO



Dr. Fadi Ayoub, Assistant Professor in the restorative department at the University at Buffalo School of Dental Medicine in New York